Head and neck cancer: who works on it

One card per institution. Pick a target to see only the groups that work on it.

• All targets
• PD-1 70
• PD-L1 42
• TP53 7
• EGFR 33
• PI3K 6
• STAT3 1
• BRAF 0
• AKT 2
• mTOR 0
• HER2 6
• RET 0
• MAPK 0
• ERK 0
• STING 0
• PTEN 1
• TERT 0
• CTNNB1 0
• JAK 1
• CTLA-4 4
• NRF2 0
• MYC 0
• VEGF 4
• YAP 1
• HIF-1 0
• MET 3
• AMPK 0
• CLDN18 0
• IL-6 2
• JNK 0
• PARP 1
• FGFR 1
• GPX4 0
• B7-H3 5
• COX-2 0
• LAG-3 2
• TROP2 5
• EZH2 0
• MEK 0
• METTL3 0
• CD47 1
• PIK3CA 4
• CDK4/6 2
• NLRP3 0
• ATM 0
• PKM2 0
• TNF 0
• FAK 0
• MMP-9 0
• PPAR 0
• PSMA 1
• TLR4 0
• BCL-2 0
• HSP90 0
• KRAS 0
• NOTCH1 0
• NTRK 1
• ALK 0
• CD40 1
• CDKN2A 2
• CXCR4 0

24 of 1,127 institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Epigenetic Profiling and Telomere-Orchestrated Mechanisms in HPV+ Oropharyngeal Cancer (EPiTOME-M)

  Royal College of Surgeons in Ireland· Dublin 2, Ireland· EU contribution €268,569· until Nov 2028· 2 countries

• European Commission (Horizon Europe) · HORIZON-ERC

  Endoscopic tissue time machine (EPIC)

  King's College London· London, United Kingdom· EU contribution €2,273,033· until May 2031

• European Commission (Horizon Europe) · HORIZON-EIC-ACC

  From Whisper to Voice: Real-Time on-Device Assistive AI Technology for Human Connection (Whispp)

  Whispp Bv· Leiden, Netherlands· EU contribution €2,498,319· until May 2028

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-RIA

  INHIBITING RESISTANCE TO IMMUNOTHERAPY IN HEAD&NECK CANCER BY TARGETING NETRIN-1 (NeckNET)

  Netris Pharma Sas· Lyon, France· EU contribution €7,248,398· until May 2030· 4 countries

• European Commission (Horizon Europe) · HORIZON-RIA

  Early clinical development of first-in-class EGL-001 targeting Tregs in head and neck squamous cell carcinoma, supported by AI-based pathomics (NEOTREG)

  Egle Therapeutics· Suresnes, France· EU contribution €7,999,120· until Nov 2028· 4 countries

• European Commission (Horizon Europe) · HORIZON-RIA

  FIRST-IN-CLASS BIOLOGICALLY TARGETED RADIOTHERAPY FOR HEAD AND NECK CANCERS (HNCS) (BIOTARGET0010)

  Universidad de Granada· Granada, Spain· EU contribution €7,591,998· until Nov 2030· 3 countries

• European Commission (Horizon Europe) · HORIZON-IA

  Unified digital platform for multimodal, multiscale, broadband, hyperspectral imaging (PHOTOMIX)

  Cy.r.i.c Cyprus Research and Innovation Center Ltd· Lefkosia, Cyprus· EU contribution €4,994,238· until Nov 2029· 6 countries

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  Morphomolecular diagnostics of head and neck cancer (LEAN)

  King's College London· London, United Kingdom· EU contribution €150,000· until Apr 2027

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  Virus-Inspired Colorectal Cancer Treatment through an Orally Administered Vaccine (VICTORY)

  Universitaetsklinikum Aachen· Aachen, Germany· EU contribution €150,000· until Dec 2026

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Label-Free Raman Approaches for Patient-Specific Biochemical Tumor Mapping to Monitor Personalized Anticancer Resistance Simulation (RAMPART)

  Politecnico di Milano· Milano, Italy· EU contribution €209,483· until May 2027· 3 countries

  The disease is named only in the funder's project summary, not in the title.

10 of 12 running projects, newest first. Listed amounts together: €36.6m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Suspended

  Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer

  NCT01810913· National Cancer Institute (NCI)· Updated 12 Nov 2026

  “Other - Assessing accrual feasibility”Registry text, quoted unchanged. Source

• Terminated

  Efficacy of an Oral Immunomodulatory Nutrient on Survival During Postoperative Concomitant Chemoradiotherapy in Head and Neck Cancer

  NCT04001543· Institut du Cancer de Montpellier - Val d'Aurelle· Updated 9 Nov 2026

  “A change in patient care. Competing trials with the expansion of immunotherapies, Difficulties in manufacturing and obtaining products for double-blind studies. The health situation, with an temporary halt due to COVID-19.”Registry text, quoted unchanged. Source

• Terminated

  Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination

  NCT04868877· Merus B.V.· Updated 26 Oct 2026

  “The Sponsor terminated the trial early for strategic business reasons. This isn't related to any safety/efficacy/clinical activity/benefit-risk concern with petosemtamab. Ongoing participants will have access to treatment outside of this trial.”Registry text, quoted unchanged. Source

• Terminated

  A Study of E7130 in Participants With Solid Tumors

  NCT03444701· Eisai Co., Ltd.· Updated 23 Oct 2026

  “The trial was prematurely terminated due to the sponsor's decision.”Registry text, quoted unchanged. Source

• Withdrawn

  Digital Phenotyping of Psychological Distress in Skin Cancer Patients

  NCT07670403· West China Hospital· Updated 16 Oct 2026

  “poor accrual”Registry text, quoted unchanged. Source

• Withdrawn

  A Clinical Study on Neoadjuvant Treatment of Resectable Head and Neck Squamous Carcinoma With Immune-targeted Therapy and Lysogenic HSV Virus

  NCT06741982· West China Hospital· Updated 16 Oct 2026

  “The study was withdrawn prior to participant enrollment due to administrative and protocol optimization considerations.”Registry text, quoted unchanged. Source

• Terminated

  A Study to Test Different Doses of BI 765049 Alone and in Combination With Ezabenlimab in Asian People With Advanced Cancer (Solid Tumours) Positive for B7-H6

  NCT06091930· Boehringer Ingelheim· Updated 14 Oct 2026

  “Sponsor decision”Registry text, quoted unchanged. Source

• Terminated

  Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies

  NCT03881488· Compass Therapeutics· Updated 9 Oct 2026

  “The combination therapy arm of the study with pembrolizumab did not yield an efficacy signal, so enrollment into the combination therapy arm was terminated. The monotherapy arm of the study was fully enrolled and completed.”Registry text, quoted unchanged. Source

• Withdrawn

  Risk-adapted Therapy in HPV-positive Oropharyngeal Cancer Using Circulating Tumor (ct) HPV DNA Profiling (ReACT 2.0)

  NCT07513324· Dana-Farber Cancer Institute· Updated 8 Oct 2026

  “study halted prematurely prior to enrollment of first participant”Registry text, quoted unchanged. Source

• Terminated

  Mental Health App for Cancer Survivors Study

  NCT06472726· University of Wisconsin, Madison· Updated 2 Oct 2026

  “App developer is no longer in business”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers

  NCT05063552· National Cancer Institute (NCI)· Source

• Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer

  NCT07667400· National Cancer Institute (NCI)· Source

• Testing Immunotherapy Versus Observation in Patients With HPV Throat Cancer

  NCT03811015· National Cancer Institute (NCI)· Source

• Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck

  NCT05172258· National Cancer Institute (NCI)· Source

• Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma

  NCT04671667· National Cancer Institute (NCI)· Source

• Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer

  NCT05172245· National Cancer Institute (NCI)· Source

• Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment

  NCT06589804· National Cancer Institute (NCI)· Source

• BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study

  NCT05136196· National Cancer Institute (NCI)· Source

• Antibiotic Treatment Effects on Intratumoral Bacteria Modulation in Surgical Patients With Oral Cancer

  NCT06627270· Case Comprehensive Cancer Center· Source

• Unplanned Hospitalization and Emergency Department Use in Patients With Head and Neck Cancer Receiving Radiotherapy

  NCT07929194· Xiangya Hospital of Central South University· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 84
• Organoids 23
• Mendelian Randomization Analysis 49
• CRISPR-Cas Systems 13
• Gene Expression Profiling 244
• Sequence Analysis, RNA 26
• Whole Genome Sequencing 7
• Exome Sequencing 22
• Proteomics 65
• Metabolomics 43
• Mass Spectrometry 14
• Flow Cytometry 56
• Immunohistochemistry 333
• Liquid Biopsy 34
• Circulating Tumor DNA 57
• Xenograft Model Antitumor Assays 307
• Positron-Emission Tomography 83
• Magnetic Resonance Imaging 276
• Machine Learning 232
• Deep Learning 187
• Cohort Studies 296
• Genome-Wide Association Study 55

• Integrating plasma-derived circulating proteins with multi-omics approaches to identify potential therapeutic targets for esophageal adenocarcinoma.

  Anal Methods, Oct 2026

• Meta-analysis of 990 EBV genomes identifies EBER2 SNP7048 and its interaction with HLA-A*11:01 driving nasopharyngeal carcinoma risk.

  Proc Natl Acad Sci U S A, Oct 2026

• Causal association between fibroblast growth factors (FGFs) and gastric cancer: A two-sample Mendelian randomization study.

  Int J Biol Markers, Oct 2026

• Genetically informed prioritization of immune checkpoint-associated genes in head and neck cancer highlights HGF and AKT1.

  Funct Integr Genomics, Sept 2026

• A Guide for Exploring Pleiotropic Associations in Genome-Wide Association Studies Using Summary Statistics.

  Stat Med, Sept 2026

• Association Between Oral Cavity Cancer and Lymphoma: A Bidirectional Mendelian Randomization Analysis.

  Oral Health Prev Dent, Aug 2026

• Causal Association Between Antidepressant Use and Thyroid Disease Risk: A Two-Sample Mendelian Randomization Study.

  Actas Esp Psiquiatr, Aug 2026

• A Two-Sample Mendelian Randomisation Analysis of the Oral Microbiome and Oral/Oropharyngeal/Tongue Cancers.

  Oral Health Prev Dent, Aug 2026

• Multi-Omics Profiling Identifies Novel Therapeutic Targets and Pathobiological Mechanisms in Oral Cancer.

  J Cell Mol Med, Aug 2026

• Deciphering the Relationship Between Alcohol Consumption, Oropharyngeal Cancers, and Socioeconomic Determinants.

  Alcohol Clin Exp Res (Hoboken), Aug 2026

See which targets of this disease your abstract mentions, and go to the people working on them.